Sorafenib

Catalog No.S7397

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Sorafenib Chemical Structure

Sorafenib Chemical Structure
Molecular Weight: 464.82

Validation & Quality Control

Cited by 60 publications:

7 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Sorafenib is available in the following compound libraries:

Product Information

  • Compare Raf Inhibitors
    Compare Raf Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Targets Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)

 View  More

IC50 6 nM 15 nM 20 nM 22 nM
In vitro Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MV-4-11MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnThTWM2OD1yLkCwNFAxOzB|IN88US=>Mlz3V2FPT0WU
MONO-MAC-6MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\vbGxmUUN3ME2wMlAxPDF6IN88US=>NEHTXHNUSU6JRWK=
ALL-POMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTBwMEOxPFQh|ryPM4[zTXNCVkeHUh?=
NKM-1NHjKZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPxSY1KSzVyPUCuNFc1OTZizszNM4DqcXNCVkeHUh?=
CGTH-W-1M3Pk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M372eWlEPTB;MD6yOVAzOiEQvF2=Ml3lV2FPT0WU
BB65-RCCMkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfvUIc2UUN3ME2wMlQ4ODd|IN88US=>M2PDdHNCVkeHUh?=
NOS-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVy3Wm5qUUN3ME2wMlU3OzZizszNM4XZSnNCVkeHUh?=
SH-4NETyVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTBwNkW2NVMh|ryPM3nJW3NCVkeHUh?=
HOP-62M2fQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHK3TnlKSzVyPUCuPFUxQDhizszNNWfUVmNPW0GQR1XS
HCC2998M3ywU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTBwOEi4NVgh|ryPMVzTRW5ITVJ?
GDM-1NEDFTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vLRmlEPTB;MD65NFY6QCEQvF2=M1ftfXNCVkeHUh?=
KM12MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXk[Y9kUUN3ME2xMlAzODl6IN88US=>MUHTRW5ITVJ?
LB2518-MELMmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\5SYZKSzVyPUGuNlA5ODlizszNM1vFRXNCVkeHUh?=
NCI-H1436NFHR[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnHRYpKSzVyPUGuNlE3PzhizszNNYLQU5BRW0GQR1XS
EM-2MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTFwM{W1O|gh|ryPMn\aV2FPT0WU
LAMA-84MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zLe2lEPTB;MT6zO|Y1QCEQvF2=NXz1PIU2W0GQR1XS
KG-1Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrPUWNKSzVyPUGuOFc6OzVizszNMmfNV2FPT0WU
A388MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTFwNUmxOlUh|ryPMVPTRW5ITVJ?
no-10NYT3SnpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHn3UFdKSzVyPUGuOlE4OjZizszNMnPsV2FPT0WU
SF126NUHwV3E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\HTWM2OD1zLk[zPFEzKM7:TR?=MoLTV2FPT0WU
MEG-01NVL1OINpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHNOGk1UUN3ME2xMlgxQThizszNMXfTRW5ITVJ?
A3-KAWMmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnG1TWM2OD1zLki4OFIh|ryPM2nXSXNCVkeHUh?=
D-247MGNUiyVFh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUGxV5d5UUN3ME2yMlE1PDhizszNMmXYV2FPT0WU
OVCAR-4MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHJTWM2OD1{LkKxN|k{KM7:TR?=NWrkZ2ppW0GQR1XS
NCI-SNU-1NHP3Z2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXVTWM2OD1{LkOxOlIh|ryPNVzaelAxW0GQR1XS
NCI-H2171M{Pyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTJwM{m3OlQh|ryPNHrybI9USU6JRWK=
SIG-M5NIm2T5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWP0RYRRUUN3ME2yMlQzOjR{IN88US=>M1zwXXNCVkeHUh?=
BE-13NHu0VGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXKWJVKSzVyPUKuOlk3ODlizszNM1rIZnNCVkeHUh?=
K052NWrNPGdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3ToSmlEPTB;Mj63OFYyPiEQvF2=NFrmZ3BUSU6JRWK=
L-540NYDQbI9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\NTWM2OD1{Lke1O|g6KM7:TR?=MXrTRW5ITVJ?
KMOE-2MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTJwOEGzOUDPxE1?NYH0ZlNJW0GQR1XS
MFH-inoM2W0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jCdGlEPTB;Mj65NlE5PSEQvF2=MoLOV2FPT0WU
HL-60M1:xUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjYTWM2OD1|LkC2Nlk6KM7:TR?=MXHTRW5ITVJ?
HCC2218M1vVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjPOGt6UUN3ME2zMlEzODB|IN88US=>MYDTRW5ITVJ?
TE-5MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTNwMUOxOlIh|ryPM33ud3NCVkeHUh?=
MZ1-PCMnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTNwNEe1NFkh|ryPMn\CV2FPT0WU
MRK-nu-1NW\1bHpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3WTHBnUUN3ME2zMlYyPDZ6IN88US=>MmiyV2FPT0WU
MZ7-melMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjwVotKSzVyPUOuOlYxQTlizszNMYDTRW5ITVJ?
BC-1NUHMWYQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXPfVNrUUN3ME2zMlc1ODJizszNMUfTRW5ITVJ?
ST486M37yS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLhW2JtUUN3ME2zMlg{Pjd|IN88US=>NWHYPVFXW0GQR1XS
KS-1M4XRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\yc5NKSzVyPUOuPFgyQThizszNNUTVbZJvW0GQR1XS
SK-NEP-1NFrieo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEi5d5pKSzVyPUSuNVY5OTVizszNMlHiV2FPT0WU
BC-3MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXzeFlUUUN3ME20MlI{OzlzIN88US=>MWXTRW5ITVJ?
NCI-H1581NEm5UHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTRwMki3PVgh|ryPMkjBV2FPT0WU
MHH-PREB-1NE\BVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{Xhd2lEPTB;ND60NFQ5PCEQvF2=NVXofoJuW0GQR1XS
NOMO-1NXu0XZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInSXG9KSzVyPUSuOFg6ODVizszNMVHTRW5ITVJ?
QIMR-WILMmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTVwMEeyPVQh|ryPNE\DV2pUSU6JRWK=
SF539M3;EdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTVwMUOyNlch|ryPM2\idXNCVkeHUh?=
TE-12MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTPOIZyUUN3ME21MlI1QTJ7IN88US=>NEThdXZUSU6JRWK=
NCI-H510AMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTVwNEG2PFUh|ryPNH;zUHhUSU6JRWK=
JARMn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLNcHhKSzVyPUWuOVA5OjRizszNMoTCV2FPT0WU
no-11NHnjeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTQTWM2OD13LkezOVY5KM7:TR?=MmW1V2FPT0WU
BV-173MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHsSmdKSzVyPUWuPVU3QDJizszNNUXSTYppW0GQR1XS
SRNWThXGdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHNOG1KSzVyPU[uNFA3PzhizszNNWHkeG0zW0GQR1XS
MOLT-16NFPHVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Xmc2lEPTB;Nj6yOVI3PiEQvF2=MnPJV2FPT0WU
MZ2-MELMnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXvOmlKSzVyPU[uN|E5OzlizszNNVTGNJJ4W0GQR1XS
SW954M4jWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPVeZlZUUN3ME22MlQ2QDZ4IN88US=>NVrl[IQ{W0GQR1XS
ML-2MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTZwNUK4OFkh|ryPMnHlV2FPT0WU
OCI-AML2MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX[4Xmw5UUN3ME22MlYyODZ{IN88US=>M1XVRXNCVkeHUh?=
SIMANX7y[Y1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3z2T2lEPTB;Nz6wNFExOSEQvF2=MnPRV2FPT0WU
DOHH-2M{naV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLWRYFuUUN3ME23MlA2Pjd4IN88US=>MXPTRW5ITVJ?
697M2LaXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTXWm5[UUN3ME23MlA2QTh7IN88US=>MV3TRW5ITVJ?
NB1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFKwcVRKSzVyPUeuOFA1ODdizszNMWTTRW5ITVJ?
D-392MGNGLpVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPjXpZKSzVyPUeuOlI3PjNizszNMojsV2FPT0WU
ES8NEfM[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTLTWM2OD15Lke2OVA{KM7:TR?=NH35[4JUSU6JRWK=
RPMI-8226MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\PTWM2OD15Lki0OVEyKM7:TR?=MWHTRW5ITVJ?
IST-MEL1Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjXTWM2OD16LkSwNFAzKM7:TR?=MWLTRW5ITVJ?
NB14MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3sSIhpUUN3ME24MlY{OTN|IN88US=>M3\PNHNCVkeHUh?=
HD-MY-ZNX\I[nVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rYVmlEPTB;OD62N|c1PiEQvF2=NH;vXodUSU6JRWK=
TE-10NF\uS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRThwN{[zOVMh|ryPM4nDXnNCVkeHUh?=
LC-1FMn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXRR2xKSzVyPUmuNVA5OzRizszNMoD0V2FPT0WU
OS-RC-2NH\tSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3hTWM2OD17LkGxNlQ{KM7:TR?=NIPZeXNUSU6JRWK=
NCI-SNU-16NWX1U|k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PYVWlEPTB;OT6yNVAzPiEQvF2=NIDON5NUSU6JRWK=
SHP-77NEfU[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlO5TWM2OD17LkexOlYzKM7:TR?=MmXUV2FPT0WU
A4-FukM3nMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnpUJhKSzVyPUmuO|U3OSEQvF2=M{eyXHNCVkeHUh?=
NB6MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTlwN{[wNlkh|ryPNVrpWZJqW0GQR1XS
JiyoyeP-2003NIHiR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTFyLkS3OFUh|ryPMXTTRW5ITVJ?
DMS-114MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\MbmlEPTB;MUCuOVQ1OSEQvF2=NUTQdpJoW0GQR1XS
NB7MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYiwT2U1UUN3ME2xNE44PTJ4IN88US=>NVq5fFU5W0GQR1XS
NCI-H747MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrkSlJmUUN3ME2xNU4yOjF4IN88US=>NVG4WJBrW0GQR1XS
HHM1LRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLIcnhKSzVyPUGxMlM5PzZizszNMoTXV2FPT0WU
EW-18NUm1[pVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPBTWM2OD1zMT65NFQ1KM7:TR?=MlLCV2FPT0WU
CHP-126NHfWe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXyzd4JvUUN3ME2xNU46PzN6IN88US=>MXHTRW5ITVJ?
NTERA-S-cl-D1Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIX2bXVKSzVyPUGyMlAzPzhizszNMlmzV2FPT0WU
DELMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmS5TWM2OD1zMj6wPVg2KM7:TR?=MmXkV2FPT0WU
LU-139MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjyOol[UUN3ME2xNk42PDF|IN88US=>MmPXV2FPT0WU
P30-OHKM2rnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHridG5KSzVyPUGyMlU1PzlizszNNEPkZ5JUSU6JRWK=
NCI-H1522M3PTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17ueGlEPTB;MUKuO|Q3KM7:TR?=MoTHV2FPT0WU
NCI-H1299M1zCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\VTWM2OD1zMz6yPVEyKM7:TR?=MkfVV2FPT0WU
UACC-257MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;0TWM2OD1zMz61NVI3KM7:TR?=NGfV[4JUSU6JRWK=
Calu-6NVjXOGIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zQS2lEPTB;MUOuOlA1PiEQvF2=NFTa[mFUSU6JRWK=
NCI-H1882NWf3Z|NwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTF|Lki1OVUh|ryPMo\FV2FPT0WU
BB30-HNCM4HiO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjUPYlKSzVyPUG0MlA3ODlizszNNFvvXoZUSU6JRWK=
ES1NGPN[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHv0Z|RKSzVyPUG0MlE2PTFizszNMk\EV2FPT0WU
NCI-H1694NF3GcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTF2LkS4NVEh|ryPNEX0NY1USU6JRWK=
IST-SL1M{HzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXKVHU1UUN3ME2xOE46PjF4IN88US=>NUHKRmFxW0GQR1XS
ECC4MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LGSmlEPTB;MUWuNFU2QCEQvF2=M4HseHNCVkeHUh?=
MDA-MB-134-VIMoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3LdnJNUUN3ME2xOU41OTNzIN88US=>MUTTRW5ITVJ?
SCHMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvOXINDUUN3ME2xOU41PzJ6IN88US=>NGGyeoxUSU6JRWK=
SK-N-FINXzWfo95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nNOWlEPTB;MUWuOlU{PCEQvF2=M4PYfXNCVkeHUh?=
HDLM-2MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XTcmlEPTB;MU[uNFcyPCEQvF2=NIf1PXBUSU6JRWK=
Ramos-2G6-4C10M3PLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDjcmFVUUN3ME2xOk4yOjl5IN88US=>MUnTRW5ITVJ?
EW-24NED6UWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPNV3dKSzVyPUG2MlE3PjFizszNM4PUPXNCVkeHUh?=
NCI-H2141NY[4cXBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrvcnExUUN3ME2xOk4yQDlizszNMXXTRW5ITVJ?
LC4-1NY\NelRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTF4Lk[xNVkh|ryPMljxV2FPT0WU
HT-144NGP4Um9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTF5LkCwOkDPxE1?MnnJV2FPT0WU
SK-MEL-1M2HlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXi0ZmN{UUN3ME2xO{4xODd{IN88US=>NV[2V4lIW0GQR1XS
SCC-15NULFR25vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTTVJpqUUN3ME2xO{4yPjN6IN88US=>NV[wO3RoW0GQR1XS
C8166M2fMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3G5XWlEPTB;MUeuOlg{OyEQvF2=MV;TRW5ITVJ?
GOTOM2TtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTF5LkizOFQh|ryPMnjZV2FPT0WU
COR-L279MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTF6LkGzOlIh|ryPNVvYemNvW0GQR1XS
K-562NUnpW2RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjVfHZKSzVyPUG4MlcyPDNizszNMnPzV2FPT0WU
ES3MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDMTWM2OD1zOD64NFQyKM7:TR?=NFn0WWVUSU6JRWK=
LU-165MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXvTWM2OD1zOT63NFA5KM7:TR?=MnXxV2FPT0WU
KM-H2M2CwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEixOodKSzVyPUKwMlMyQDRizszNMki0V2FPT0WU
RLNHTve21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\VcJJKSzVyPUKwMlk3QTJizszNM3;6ZnNCVkeHUh?=
EW-3NWPvZ|RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDYTWM2OD1{MT6xPFg6KM7:TR?=MoHXV2FPT0WU
A101DNXLGU3ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTJzLkO3OVIh|ryPM2TFS3NCVkeHUh?=
HUTU-80NEnzS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTJzLkO5OFYh|ryPNWfjfJNDW0GQR1XS
NCI-H23MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTJzLkO5PVIh|ryPMVHTRW5ITVJ?
PF-382MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTHTpRMUUN3ME2yNU41PDB|IN88US=>NXXjPFkxW0GQR1XS
LB373-MEL-DMnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvGWHpKSzVyPUKxMlU3OTVizszNMljvV2FPT0WU
TE-8NIC3fJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDZV3NKSzVyPUKxMlY{QTRizszNM2jpSXNCVkeHUh?=
TE-9NYjsfYVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTJzLki1NVMh|ryPMoXoV2FPT0WU
DaudiM1LGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnRNmJKSzVyPUKxMlk{ODRizszNNITURYhUSU6JRWK=
D-542MGNHu4boVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLuTWM2OD1{Mj6wNlU3KM7:TR?=MlzuV2FPT0WU
U-698-MNU[wcIs4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTJ{LkS2NFMh|ryPMlPSV2FPT0WU
ES6MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTJ{LkezOlYh|ryPMW\TRW5ITVJ?
DU-4475NYfmdod4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;zTWM2OD1{Mz64PFk4KM7:TR?=NYL4d49KW0GQR1XS
ECC12NXO2R5FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTJ2LkK4NFMh|ryPMkHXV2FPT0WU
C2BBe1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTKR3N6UUN3ME2yOE4{OjN7IN88US=>Mne5V2FPT0WU
IST-SL2NHW3d5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIr0T3NKSzVyPUK0MlQ{PjJizszNMXTTRW5ITVJ?
DJM-1NH;le25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTJ2LkWyNlEh|ryPMVrTRW5ITVJ?
DMS-153M2[xcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzFflRxUUN3ME2yOE45PjF2IN88US=>Ml[1V2FPT0WU
NB13NFy1UJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1WwUWlEPTB;MkWuNFI3PSEQvF2=MXvTRW5ITVJ?
SK-N-DZMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTINI9KSzVyPUK2MlM1OTRizszNM{HUUnNCVkeHUh?=
COR-L88NIPOR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjxTWM2OD1{Nj61O|k3KM7:TR?=MVXTRW5ITVJ?
LU-65NGnwVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\2TWM2OD1{Nj64OVM2KM7:TR?=NU[3XoNLW0GQR1XS
TGBC1TKBMlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrPS5VsUUN3ME2yOk46QDJ6IN88US=>M1nWVnNCVkeHUh?=
THP-1NHvYRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPKTWM2OD1{Nz6yNVQyKM7:TR?=MXjTRW5ITVJ?
ONS-76NHXlXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHixWpNKSzVyPUK3MlM{OiEQvF2=NEXvNIpUSU6JRWK=
LC-2-adNXrve5ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV60N5NyUUN3ME2yO{43OjNzIN88US=>NHjWXJNUSU6JRWK=
EW-13MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XLRmlEPTB;MkmuNVc1PiEQvF2=MkDxV2FPT0WU
MS-1M3r4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrPTWM2OD1|MD63Nlc5KM7:TR?=NYrDVnFmW0GQR1XS
NCI-H2227MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfVRVQyUUN3ME2zNE46QDB4IN88US=>M{TXbHNCVkeHUh?=
LXF-289MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjxTWM2OD1|MT60OFkzKM7:TR?=MYrTRW5ITVJ?
MC116MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE[1dIZKSzVyPUOyMlA5OjZizszNNXzBOJpNW0GQR1XS
EVSA-TNF20b2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTN{LkK1PFUh|ryPM{HIUXNCVkeHUh?=
CTB-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PLe2lEPTB;M{OuNVExOSEQvF2=MVjTRW5ITVJ?
COLO-320-HSRMlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTN|LkG2NFMh|ryPM{\kO3NCVkeHUh?=
NCI-H2196NGD6eWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjucocxUUN3ME2zN{4zPTV5IN88US=>MnjZV2FPT0WU
LB2241-RCCM1K1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH70[2hKSzVyPUOzMlMyOzVizszNNFf4e|JUSU6JRWK=
LS-513MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXz5dZVLUUN3ME2zN{45PjN6IN88US=>M3r4TnNCVkeHUh?=
LP-1NV[2bGtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkT6TWM2OD1|Mz65PVU3KM7:TR?=MlP2V2FPT0WU
A253MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkW2TWM2OD1|ND6yNlk3KM7:TR?=MmDCV2FPT0WU
SK-MM-2NXrHTWZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTN2Lkm0OVEh|ryPMkW4V2FPT0WU
NCI-H1963NVr1N4RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHNTWM2OD1|NT6zNFczKM7:TR?=NYXtfnZFW0GQR1XS
MMAC-SFNYGwNYdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PXR2lEPTB;M{WuPFc5PSEQvF2=M1Xse3NCVkeHUh?=
LB831-BLCMnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTN4LkC2OVQh|ryPMmn3V2FPT0WU
WSU-NHLMl7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTN4LkG2OEDPxE1?MWPTRW5ITVJ?
CESSMmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{H0VmlEPTB;M{[uNlg1QCEQvF2=NFvh[ZZUSU6JRWK=
NEC8MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\KbVNSUUN3ME2zOk42QDN3IN88US=>MlTMV2FPT0WU
KNS-42NH7wSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEGwNoFKSzVyPUO3MlEzOzdizszNNIfHdG5USU6JRWK=
MHH-CALL-2NWfM[5R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLHOXE4UUN3ME2zO{4yQDJzIN88US=>NUTsTZVKW0GQR1XS
K5NVTPZYl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTUVJhyUUN3ME2zPE41OyEQvF2=M2X4WXNCVkeHUh?=
CP66-MELMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLSTWM2OD1|OT6wO|M{KM7:TR?=NHn4b49USU6JRWK=
OPM-2NILob45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWezNmRlUUN3ME2zPU45PDN{IN88US=>M1zvbXNCVkeHUh?=
IST-MES1M3T6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1THO2lEPTB;NECuN|A6PiEQvF2=NWe1TmUyW0GQR1XS
EC-GI-10MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTKRWJKSzVyPUSxMlU5ODVizszNNEDtO3lUSU6JRWK=
CTV-1NVTHVphYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTR{Lki0NFYh|ryPNV;3XXlSW0GQR1XS
DG-75MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTR|Lke1PVUh|ryPNIPvRXlUSU6JRWK=
KNS-81-FDM1\PbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTR3LkSwOVgh|ryPMoSwV2FPT0WU
NCI-H82Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTR3LkW3OVgh|ryPMorsV2FPT0WU
RPMI-8866NEXyUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlGyTWM2OD12Nj6xPFc{KM7:TR?=MWnTRW5ITVJ?
ACNM1f2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MortTWM2OD12Nj60N|Qh|ryPM3HaZ3NCVkeHUh?=
NCI-H1395MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFz1VZZKSzVyPUS2MlQ4PTZizszNMlfTV2FPT0WU
NCI-H209NIjYNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLtUlJKSzVyPUS3MlE1ODVizszNNVPGcnhKW0GQR1XS
TGWMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1H6fGlEPTB;NEmuNFc6OSEQvF2=M32zcnNCVkeHUh?=
NCI-H748M3;WdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nMOmlEPTB;NEmuOFc2OyEQvF2=NHzEO5BUSU6JRWK=
EKVXNXe3WoxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTR7Lk[2Nlgh|ryPMX7TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Biochemical assays Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.

Cell Assay:

[1]

Cell lines MDA-MB-231, and HAoSMC
Concentrations Dissolved in DMSO, final concentrations ~10 μM
Incubation Time 72 hours
Method

Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.

Animal Study:

[1]

Animal Models Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
Formulation Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
Dosages ~60 mg/kg
Administration Orally once daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Wilhelm SM, et al. Cancer Res, 2004, 64(19), 7099-7109.

[2] Liu L, et al. Cancer Res, 2006, 66(24), 11851-11858.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02747537 Not yet recruiting Pediatric Solid Tumors Washington University School of Medicine July 2016 Phase 2
NCT02691780 Not yet recruiting Refractory Solid Tumors Samsung Medical Center May 2016 --
NCT02774187 Recruiting Hepatocellular Carcinoma Sun Yat-sen University May 2016 Phase 3
NCT02616692 Recruiting Hepatocellular Cancer Bayer May 2016 --
NCT02728050 Not yet recruiting Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|de Novo Myelodysplastic Syndrome|Myeloproliferative Neoplasm University of Washington|National Cancer Institute (NCI) May 2016 Phase 1|Phase 2

view more

Chemical Information

Download Sorafenib SDF
Molecular Weight (MW) 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms BAY 43-9006
Solubility (25°C) * In vitro DMSO 63 mg/mL warming (135.53 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide

Customer Product Validation(7)


Click to enlarge
Rating
Source J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck
Method Western blot
Cell Lines human melanoma cell lines M14 and WM-115
Concentrations 10 μM
Incubation Time 48 h
Results To see whether inhibition of this pathway has an impact on the expression of Plk-1 in human melanoma, we used specific inhibitors of mitogen-activated protein kinase kinase (MEK) 1/2 (PD98059), multikinase inhibitor (sorafenib), c-Jun N-terminal kinase (JNK) (JNK inhibitor II), and the p38 MAPK (SB203580). Treatment of human melanoma cell lines WM-115 and M14 with these inhibitors was accompanied with significant reduction of Plk-1 protein levels (Figure a). This phenomenon was accompanied by induction of apoptosis(Figure b).

Click to enlarge
Rating
Source J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck
Method Immunoreactivity
Cell Lines Hair cells
Concentrations 500 nM
Incubation Time 1 h
Results To illustrate the time-dependency of JNK activation, mouse utricle and cochlea cultures were incubated for different time periods with 200 uM gentamicin, with or without a pre-incubation with 500 nM sorafenib for 1h (sorafenib was present during entire culture period). A illustrates the time-dependent activation of the JNK pathway in mouse utricles, as evident in the phosphorylation of JNK and its substrate c-Jun. In agreement with an involvement of MLK7, sorafenib nearly completely prevented JNK and c-Jun phosphorylation (B).

Click to enlarge
Rating
Source Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck
Method Western blot analysis
Cell Lines A549, H460, H838 cells
Concentrations 1-3 uM
Incubation Time 48 h
Results It have therefore measured phosphorylation of AMPKa at its activation site Thr172 after treatment of cells with sorafenib, metformin or the combination thereof. A and b show an unexpected activation of AMPKa, as judged by Thr172 phosphorylation, by sorafenib treatment alone. Importantly, AMPK activation was increased significantly when sorafenib was combined with metformin, independent of LKB1 or KRAS mutation status (a and b). Increased AMPK activation was also observed when cells were treated with sorafenib in combination with the AMPK activators salicylate (c).

Click to enlarge
Rating
Source Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck
Method qRT-PCR
Cell Lines Tumor cells
Concentrations 1 uM
Incubation Time 24 h
Results Furthermore, siRNA-mediated knockdown of linc-VLDLR using 2 different siRNA (siRNA-linc-VLDLR-1 or siRNA-linc-VLDLR-2) decreased cell viability in response to sorafenib, doxorubicin, or camptothecin. Thus, VLDLR represents a stress-responsive lncRNA that can be induced by exposure to chemotherapy and that can contribute to acquired chemoresistance in HCC cells. We observed that linc-VLDLR was also increased in EV released from these tumor cells exposed to these anticancer agents.

Click to enlarge
Rating
Source Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck
Method Immunohistochemistry
Cell Lines HuH7 cells
Concentrations 25 mg/kg
Incubation Time 3 days
Results Combined exposure to sorafenib and PX-866 reduced tumor growth to a greater extent than either individual drug. Isolation of tumors at day 15 revealed that the drug combination caused morphologic alterations in the tumor (H&E staining), reduced proliferation (Ki67 staining), decreased phospho-ERK1/2 staining, and increased levels of tumor cell apoptosis (cleaved caspase 3).

Click to enlarge
Rating
Source Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck
Method Western blot analyses
Cell Lines HepG2 cells
Concentrations 0.1 uM
Incubation Time 1 h
Results Pretreatment with sorafenib and sunitinib reduced the LicA-induced cell death and ER stress responses, including CHOP induction, ATF6a and caspase-4 cleavage, and eIF2a phosphorylation. In contrast, sunitinib and sorafenib did not alter TG-induced cell death or ER stress responses.

Click to enlarge
Rating
Source PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck
Method MTT assay
Cell Lines Huh7, THLE2, Hep3B cells
Concentrations 0.016-50 uM
Incubation Time 72 h
Results Cytotoxicity by sorafenib was measured by MTT assay atvarying concentrations on the HCC lines Huh7, THLE2, Hep3B.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Raf Products

  • LY3009120

    LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.

  • GDC-0994

    GDC-0994 is a potent, orally available ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.

  • Ulixertinib (BVD-523, VRT752271)

    Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.

  • Vemurafenib (PLX4032, RG7204)

    Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM in cell-free assay.

    Features:A novel and potent inhibitor of the B-RAFV600E oncoprotein.

  • Dabrafenib (GSK2118436)

    Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.

  • Sorafenib Tosylate

    Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

  • PLX-4720

    PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

  • TAK-632

    TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.

  • GDC-0879

    GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.

  • GW5074

    GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.

Recently Viewed Items

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us